Harwood Feffer LLP Announces Investigation of Rockwell Medical, Inc.

NEW YORK, March 8, 2016

In January 2015, Rockwell announced that the FDA approved the Company's drug, Triferic, for sale. Thereafter the Company stated it anticipated broad clinical adoption of Triferic. 

On February 29, 2016, on an investor conference call a Company representative admitted to investors that sales of Triferic were "immaterial" for 2015. On that news, Rockwell stock fell over 30%.

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own Rockwell shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com 
Website: http://www.hfesq.com 
Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.